Searched for
CHANDRU CHAWLA
Living with less: How pandemic has inspired some people to make permanent changes in their livesDuring the lockdown, people were forced to make do with less. Now, some are carrying on with this life lesson, cutting down on city life, e...- After Market: MCX under Sebi lens; details of insider trade & block dealsDespite the equity benchmarks rising to record highs, 250 stocks hit fresh 52-week lows today.
- Cipla divests 16.7 per cent stake in Chase Pharma to AllerganChase was recently financed by a Series B consortium consisting of New Rhein Healthcare, Edmond de Rothschild Investment Partners and Cipla...
- Stempeutics research gets DCGI nod for stem cell based productThe company's goal is to globalise Stempeucel for Buerger's Disease and the market size is approximately $ 1.5 billion worldwide.
- IIM Bengaluru to host Innovation, IP ConferenceIIM Bengaluru announced that it would host the first India Conference on Innovation, Intellectual Property and Competition on December 7-8.
- Cipla to sell entire stake in Biomab Holding for $25,775,000Drug major Cipla has entered into an agreement to sell its entire stake in Biomab Holding to Biomab Brilliant for a consideration of $25,77...
- Cipla's Stempeutics gets process patent for Stempeucel from JapanStempeutics has received process patent from the Japan for novel stem cell drug Stempeucel aimed at treatment of critical limb ischemia.
- Stempeutics' Stempeucel gets Orphan Drug status in EuropeAn orphan designation allows a company to benefit from incentives from the European Union to develop a medicine for a rare disease.
- Stempeutics gets EMA approval to market stem cell drug in EUThe ATMP classification, approved by the committee for Advanced Therapies (CAT) of the EMA will allow the Bengaluru- based Stempeutics to c...
- Indian biotech firm Stempeutics Research gets US Process Patent for its novel stem cell drugBacked by the Manipal Education and Medical Group and drug maker Cipla, Stempeutics makes stem cell-based drugs or regenerative medicine.
- Cipla floats in-house venture capital firmCipla's new initiative comes at a time when the company is making bold moves in expanding its international business.
- Don't look now, Cipla just might be changing, says Cipla chairman & MD Dr Yusuf HamiedET delves into why one of India's oldest and best-known pharma companies is taking a hard look at itself.
Load More
